Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BAY86-9596 · 2 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| Arm 1 | EXPERIMENTAL | - |
| Arm 2 | EXPERIMENTAL | - |
| Arm 3 | EXPERIMENTAL | - |
| Arm 4 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| BAY86-9596 | DRUG | One single dose administration of a diagnostic agent |
| Fludeoxyglucose (18F)-IBA | DRUG | Subgroup of cancer patients: radiation induced inflammation. Fluordeoxyglucose (18F)-FDG PET scan will be performed approx. 4 week after radiation and compared with tracer BAY86-9596 (acc. to Amendment 4 only in the Netherlands) |
Inclusion Criteria: * Cancer Patients * Patient had an Fluorodeoxyglucose (FDG) Positron Emission Tomography (PET)/Computer tomography(CT) performed 14 days prior to treatment with BAY86-9596 for detection, or staging, or restaging, or therapy response assessment that still showed tumor mass wit...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Hologic, Inc. | HOLX | 1 | N/A | Undisclosed |
| Intelligent Bio Solutions Inc. | INBS | 1 | - | Undisclosed |
| HeartFlow, Inc. | HTFL | 1 | N/A | Rosuvastatin |
| GE Healthcare Technologies Inc. | GEHC | 2 | N/A | Undisclosed |
BAY86-9596 is an investigational diagnostic imaging agent being developed for use in positron emission tomography (PET) and computed tomography (CT) imaging. It is being studied to evaluate its safety, tolerability, and diagnostic performance in patients with non-small cell lung cancer, breast cancer, head and neck cancer, and inflammations.
BAY86-9596 is a small molecule used as a PET/CT imaging agent. It is designed to be administered intravenously and detected by PET/CT imaging to help visualize cancer and inflammatory conditions. The specific molecular target of BAY86-9596 has not been disclosed in the available clinical trial information.
BAY86-9596 is being developed by Lantheus Holdings, Inc. (ticker: LNTH). The company is conducting clinical trials to evaluate the imaging agent's safety, tolerability, and diagnostic performance in patients with certain cancers and inflammations.
BAY86-9596 is in Phase 1 clinical development. Two Phase 1 trials have been completed, with a total of 59 participants enrolled. The drug is investigational and has not been approved by regulatory authorities for commercial use.
BAY86-9596 has been studied in two completed Phase 1 trials. NCT01089998 enrolled 35 participants in the Netherlands and Switzerland to assess radiation dosimetry, pharmacokinetics, safety, and diagnostic performance in healthy volunteers and patients with certain cancers or inflammations. NCT01297088 enrolled 24 participants in Singapore to evaluate PET/CT imaging after a single intravenous dose in patients with cancer or inflammations.
BAY86-9596 is a fluorine-18 labeled compound, as indicated by the trial title referencing BAY86-9596 (18F). It is administered as a single intravenous dose for PET/CT imaging. The drug is also referred to as BAY86-9596 (18F) in clinical trial documentation.